



Biotechnology Innovation Organization  
1201 New York Ave., NW  
Suite 1300  
Washington, DC 20005  
202-962-9200

The Honorable Brett Guthrie  
Chairman  
Energy & Commerce Committee  
U.S. House of Representatives  
Washington, DC 20515

The Honorable Frank Pallone  
Ranking Member  
Energy & Commerce Committee  
U.S House of Representatives  
Washington, DC 20515

June 3, 2026

Dear Chairman Guthrie, Ranking Member Pallone:

On behalf of the Biotechnology Innovation Organization (BIO), I am writing to share our support for a federal comprehensive data privacy and security framework, as outlined in the Securing and Establishing Consumer Uniform Rights and Enforcement over Data Act, or SECURE Data Act (H.R. 8413).

BIO is the premier biotechnology advocacy organization representing biotech companies, industry leaders, and state biotech associations in the United States and more than 35 countries around the world. Our members research and develop breakthrough biotechnology products that save and change people's lives. More than 90 percent are small and medium-sized companies, many of which are pre-commercial, and represent the true drivers of biotechnological innovation in our nation. In fact, statistics show that more than half of all innovative medicines originate with them.

As health care transforms from traditional one-size-fits-all medical care to personalized medicine tailored to the genomic, molecular, and lifestyle characteristics of individual patients, BIO and our members stand ready to deliver further breakthrough innovations. Yet companies' ability to efficiently access and leverage health data to drive biomedical research – while appropriately protecting patient privacy – is critical to their efforts to progress commercial research and development, both domestically and globally.

The existing patchwork of various data privacy laws – across states, federal regulations, and privacy rules around the world, have created confusion and regulatory burdens that hinder coordination and collaboration amongst companies and research partners. BIO supports the SECURE Data Act's strong federal preemption provisions to ensure one uniform federal privacy standard that provides innovators with the regulatory certainty and consistency needed to advance biotechnology for the benefit of American patients.

Further, we believe that harnessing health data for biomedical R&D can continue without impinging on the protection of patients' privacy rights. H.R. 8413 strikes the appropriate balance by recognizing existing federal frameworks governing clinical trial data, as well as de-identified health data standards under HIPAA, without unduly burdening innovators with dual regulatory regimes in legitimate clinical research settings.

We look forward to continuing to work with the Committee to clarify these needs for the research community while enhancing the privacy and security of sensitive health data.

Sincerely,

A handwritten signature in black ink, appearing to read "John F. Crowley". The signature is fluid and cursive, with the first letters of the first and last names being capitalized and prominent.

John F. Crowley  
President and CEO, Biotechnology Innovation Organization (BIO)